Sunshine Biopharma (SBFM) Stock: Buy, Sell, or Hold?
SBFM - Sunshine Biopharma Inc.
$1.06
-0.02 (-1.85%)
▼
5d:
-4.5%
30d:
-12.4%
90d:
-55.27%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When SBFM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SBFM shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SBFM shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SBFM is currently trading at $1.06, which is considered oversold relative to its 30-day fair value range of $1.10 to $1.24. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.6) compared to its historical average (13.1). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SBFM is showing sideways momentum. The price is currently testing key support at $1.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SBFM scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $56.00 (+5183.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SBFM is showing sideways momentum. The price is currently testing key support at $1.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SBFM scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $56.00 (+5183.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.10 -
$1.24
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 5183.0% below Wall St target ($56.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.10 -
$1.24
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.05
Resistance Level
$1.28
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.65
Wall Street Target
$56.00
(+5183.0%)
Revenue Growth (YoY)
-1.6%
Profit Margin
-16.5%
PE vs Historical
-2.7 vs 13.1
CHEAP
Share & Embed Analysis
Last updated: September 14, 2026 12:35 AM ET
Data refreshes hourly during market hours. Next update: 1:35 AM
Data refreshes hourly during market hours. Next update: 1:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SBFM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary Sh… |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
